Drug Profile
PLX 100
Alternative Names: PLX-100Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Polaryx Therapeutics
- Class Acids; Small molecules
- Mechanism of Action Tripeptidyl-peptidase 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Neuronal ceroid lipofuscinosis; Niemann-Pick disease type A; Niemann-Pick disease type B
Most Recent Events
- 03 Jan 2024 Phase-I clinical trials in Neuronal ceroid lipofuscinosis (PO) (Polaryx Therapeutics pipeline, January 2024)
- 03 Jan 2024 Phase-I clinical trials in Niemann-Pick disease type A (PO) (Polaryx Therapeutics pipeline, January 2024)
- 03 Jan 2024 Phase-I clinical trials in Niemann-Pick disease type B (PO) (Polaryx Therapeutics pipeline, January 2024)